Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 9/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.49 |
| ▸ | TTK | P33981 | 5/20 | 0.46 |
| ▸ | RXRB | P28702 | 2/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1933358 | 0.85 | PIK3CG (0.46) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL1932561 | 0.85 | PIK3CG (0.46) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL9997042 | 0.84 | PIK3CG (0.53) | PIK3CGPIK3CDPIK3CAPIK3CBTTK | |
| SCHEMBL1932766 | 0.81 | PIK3CG (0.49) | PIK3CGPIK3CDPIK3CAPIK3CBTTK | |
| SCHEMBL2186588 | 0.81 | PIK3CG (0.60) | PIK3CGPIK3CDPIK3CAPIK3CBTTK | |
| SCHEMBL1933985 | 0.80 | PIK3CG (0.42) | PIK3CGPIK3CDPIK3CAPIK3CBTTK | |
| SCHEMBL936653 | 0.78 | PIK3CG (0.51) | PIK3CGPIK3CDPIK3CAPIK3CBTTK | |
| SCHEMBL9996747 | 0.78 | TTK (0.57) | PIK3CGPIK3CDPIK3CAPIK3CBTTK | |
| SCHEMBL9997011 | 0.76 | PIK3CG (0.48) | PIK3CGPIK3CDPIK3CAPIK3CBTTK | |
| SCHEMBL9998764 | 0.76 | MET (0.48) | TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9555022-B2 | Substituted triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-01-31 | — | — | US | disclosed |
| US-9555022-B2 | Substituted triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-01-31 | — | — | US | disclosed |
| EP-2699575-B1 | TRIAZOLOPYRIDINES | BAYER IP GMBH (DE) | 2015-03-25 | — | — | EP | disclosed |
| EP-2699575-B1 | TRIAZOLOPYRIDINES | BAYER IP GMBH (DE) | 2015-03-25 | — | — | EP | disclosed |
| EP-2507236-B1 | Triazolopyridine derivates | BAYER IP GMBH (DE) | 2014-12-17 | — | — | EP | disclosed |
| EP-2507236-B1 | Triazolopyridine derivates | BAYER IP GMBH (DE) | 2014-12-17 | — | — | EP | disclosed |
| US-20140120087-A1 | TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-01 | — | — | US | disclosed |
| US-20140120087-A1 | TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-01 | — | — | US | disclosed |
| EP-2699575-A1 | TRIAZOLOPYRIDINES | Bayer Intellectual Property GmbH (DE) | 2014-02-26 | — | — | EP | disclosed |
| US-20130156756-A1 | Substituted Triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130121994-A1 | TRIAZOLOPYRIDINE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20130121994-A1 | TRIAZOLOPYRIDINE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20130121994-A1 | TRIAZOLOPYRIDINE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| EP-2582699-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Intellectual Property GmbH (DE) | 2013-04-24 | — | — | EP | disclosed |
| WO-2012160029-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012160029-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012143329-A1 | TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2011157688-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011157688-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011064328-A1 | TRIAZOLOPYRIDINE DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156756-A1 | Substituted Triazolopyridines | CCND2, CCND1, QDPR | PIK3CG 1972/4885PIK3CD 1061/4885PIK3CA 1062/4885 |
| US-20140120087-A1 | TRIAZOLOPYRIDINES | QDPR, TBXA2R, KCNJ11 | PIK3CG 2510/4885PIK3CD 2009/4885PIK3CA 1875/4885 |
| US-20130121994-A1 | TRIAZOLOPYRIDINE DERIVATIVES | TTBK1, BUB1, TTK | PIK3CG 718/4885PIK3CD 430/4885PIK3CA 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.